Assess Gamma H2AX Positivity in Circulating Prostate Cancer Cells Before and After Radium 223 Treatment

Trial Profile

Assess Gamma H2AX Positivity in Circulating Prostate Cancer Cells Before and After Radium 223 Treatment

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 24 Aug 2017

At a glance

  • Drugs Radium 223 chloride (Primary)
  • Indications Adenocarcinoma; Prostate cancer
  • Focus Biomarker; Pharmacodynamics
  • Most Recent Events

    • 18 Aug 2017 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.
    • 18 Aug 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Jun 2018.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top